摘要
双联抗血小板是急性冠状动脉综合征患者抗栓治疗的基石,临床上常用的抗血小板药物主要包括阿司匹林与P2Y12受体拮抗剂。目前,新型P2Y12受体拮抗剂,尤其替格瑞洛单药治疗是抗血小板优化治疗领域正在深入研究的课题。研究发现,P2Y12受体拮抗剂可以减少血小板中的血栓素A2受体表达及血栓素A2生成。替格瑞洛具有广谱的抗血小板效应机制。本文针对新型P2Y12受体拮抗剂特别是替格瑞洛抗血小板机制的相关研究归纳总结,对优化抗血小板治疗提出新思路。
Dual antiplatelet therapy is the cornerstone of antithrombotic therapy in patients with acute coronary syndrome.Aspirin and P2Y12 receptor antagonists are commonly used antiplatelet drugs in clinic.At present,new P2Y12 receptor antagonists,especially ticagrelor monotherapy,are the subject of in-depth research in the field of antiplatelet optimization therapy.Studies have found that P2Y12 receptor antagonists can reduce thromboxane A2 receptor expression and thromboxane A2 production in platelets.Ticagrelor has broad-spectrum antiplatelet mechanism.This article summarizes the relevant research on the antiplatelet mechanism of new P2Y12 receptor antagonists,especially ticagrelor,and proposes new ideas for optimizing antiplatelet therapy.
作者
赵凯凯
白俊琴
张波
ZHAO Kaikai;BAI Junqin;ZHANG Bo(Department of Cardiology,First Affiliated Hospital,Dalian Medical University,Dalian,Liaoning 116011,China)
出处
《中国动脉硬化杂志》
CAS
2022年第2期180-184,共5页
Chinese Journal of Arteriosclerosis
